Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.97
+0.01 (+0.07%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,105,612
Open
14.87
Bid (Size)
14.71 (2)
Ask (Size)
15.07 (4)
Prev. Close
14.96
Today's Range
14.87 - 15.06
52wk Range
12.57 - 16.39
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
August 12, 2024
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...
Via
Benzinga
Exposures
Product Safety
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...
Via
PressReach
Exposures
Product Safety
Performance
YTD
+4.39%
+4.39%
1 Month
+9.27%
+9.27%
3 Month
+15.69%
+15.69%
6 Month
+2.18%
+2.18%
1 Year
-2.48%
-2.48%
More News
Read More
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
August 07, 2024
Via
Benzinga
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
August 07, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024
July 31, 2024
Via
InvestorPlace
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
July 31, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
3 Biotech Stocks to Buy on the Dip: July 2024
July 29, 2024
Via
InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
July 24, 2024
Via
Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
July 09, 2024
Via
Benzinga
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
July 06, 2024
Via
Talk Markets
Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report
July 02, 2024
Via
Benzinga
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
June 28, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Takeda Announces New Assignments of Directors
June 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
June 24, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
June 22, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
June 21, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
June 21, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
June 18, 2024
Via
Benzinga
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
June 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 17, 2024
Via
Benzinga
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
June 17, 2024
Via
Benzinga
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
June 17, 2024
Via
Benzinga
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
June 17, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
June 15, 2024
Via
Talk Markets
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
June 14, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
